Form 4: Outlook Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Faisal Ghiath Sukhtian, a director of Outlook Therapeutics, acquired stock options exercisable for 12,323 shares of common stock on February 4, 2025.
Summary
- On February 4, 2025, Faisal Ghiath Sukhtian, a director of Outlook Therapeutics, Inc., acquired stock options.
- These options grant the right to buy 12,323 shares of common stock at an exercise price of $1.825 per share.
- The options vest in three equal installments on March 31, 2025, June 30, 2025, and September 30, 2025, contingent upon continuous service to the issuer.
- Following the transaction, Sukhtian directly owns 12,323 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard regulatory filing regarding stock option grants to a director.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder confidence due to the director's increased stake in the company.
Key Dates
| Date | Description |
|---|---|
| 02/04/2025 | Date of the stock option transaction. |
| 02/04/2025 | Date the stock options were acquired. |
| 03/31/2025 | First vesting date for the stock options. |
| 06/30/2025 | Second vesting date for the stock options. |
| 09/30/2025 | Third vesting date for the stock options. |
| 02/04/2035 | Expiration date of the stock options. |
| 02/06/2025 | Date of signature for the Form 4 filing. |
Keywords
stock options, Form 4, Outlook Therapeutics, OTLK, director, insider trading, beneficial ownership, equity securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.